14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CRVL vs GOCO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Corvel Corp (CRVL) is the stronger overall head-to-head candidate over GoHealth, Inc. (GOCO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRVL carries a Unified Composite Score of 36.6/100 (SELL) at $87.48 (23.8x Forward P/E, 15.9% operating margin), whereas GOCO carries 42.9/100 (HOLD) at $0.30 (N/M Forward P/E, -292.0% operating margin).
Composite vs. Pillar Nuance: While GOCO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. CRVL 36.6/100 SELL), CRVL captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (15.9% vs. -292.0% operating margin) and revenue trajectory (+11.5% vs. -94.6% YoY).
Technical & Structure Timing Caution: CRVL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.8); meanwhile GOCO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRVL vs GOCO. Trailing 12-month operating profitability (CRVL 15.9% vs GOCO -292.0%) and valuation multiples (CRVL 23.8x vs GOCO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Insurance Brokers value chain with $8.5M market capitalization and -292.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRVL vs GOCO Key Questions & Quantitative Answers
As of Nov 17, 2026, Corvel Corp (CRVL) is the stronger overall head-to-head candidate over GoHealth, Inc. (GOCO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRVL carries a Unified Composite Score of 36.6/100 (SELL) at $87.48 (23.8x Forward P/E, 15.9% operating margin), whereas GOCO carries 42.9/100 (HOLD) at $0.30 (N/M Forward P/E, -292.0% operating margin). Composite vs. Pillar Nuance: While GOCO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. CRVL 36.6/100 SELL), CRVL captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (15.9% vs. -292.0% operating margin) and revenue trajectory (+11.5% vs. -94.6% YoY). Technical & Structure Timing Caution: CRVL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.8); meanwhile GOCO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRVL leads the Growth & Scale pillar: CRVL posts +11.5% YoY revenue growth and +24.1% YoY earnings growth on $1.01B TTM revenue (25.5% gross margin, 15.9% operating margin), compared with GOCO at -94.6% YoY revenue growth and +424.1% YoY earnings growth on $153M TTM revenue (57.3% gross margin, -292.0% operating margin). On trailing 12-month operating scale, CRVL generates $1.01B in USD-normalized revenue versus $153M for GOCO. In operating R&D and SG&A reinvestment, CRVL deploys 9.6% of Rev ($97M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GOCO.
CRVL screens cheaper on headline valuation multiples. CRVL trades at 23.8x Forward P/E, 36.0x Trailing P/E, N/M PEG, and 4.3x EV/Revenue (19.3% EBITDA margin), whereas GOCO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-96.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRVL (30.6% ROE) versus GOCO (-289.9% ROE) capital efficiency.
In options market volatility and institutional positioning, CRVL carries 187.6% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.17β · 33% Vol realized risk). By comparison, GOCO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.15β · 201% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.